...Allan D. Sniderman; Robert Scott Kiss; Thomas Reid; George Thanassoulis; Gerald F. Watts Statins and PCSK9 inhibitors dramatically lower plasma LDL levels and dramatically increase LDL receptor number within hepatocyte cell membranes. It seems self-evident that total clearance of LDL particles from...

..., which underlie vascular damage in diabetes. Statins are cholesterol-lowering drugs that are vasoprotective in diabetes through unknown mechanisms. We tested the hypothesis that atorvastatin decreases NADPH oxidase (Nox)-derived ROS generation and associated vascular injury in diabetes. Lepr db /Lepr db...

...Philip J. Millar; John S. Floras Statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) reduce plasma cholesterol and improve endothelium-dependent vasodilation, inflammation and oxidative stress. A ‘pleiotropic’ property of statins receiving less attention is their effect on the autonomic...

... LDL) (syn LDL3; D =1.044–1.063 g/ml) are increased in diabetes and are closely correlated. We studied whether SD-LDL is more susceptible to glycation in vitro than more buoyant LDL in statin- and non-statin-treated Type 2 diabetes mellitus. Serum SD-LDL apoB and glyc-apoB on statins was 20±2 (means...

...Kou-Gi Shyu; Shih-Chung Chen; Bao-Wei Wang; Wen-Pin Cheng; Huei-Fong Hung Leptin contributes to the pathogenesis of atherosclerosis. Ang II (angiotensin II), a proatherogenic cytokine, increases leptin synthesis in cultured adipocytes. Statin suppresses leptin expression in adipocytes and human...

...Luciana V. Rossoni; Mark Wareing; Camilla F. Wenceslau; Mahmood Al-Abri; Chris Cobb; Clare Austin Statins can have beneficial cholesterol-independent effects on vascular contractility, which may involve increases in the bioavailability of NO (nitric oxide) as a result of phosphorylation of eNOS...

... with the significant rise in PCSK9 levels after statin therapy, warrant further studies in order to unravel the exact role of PCSK9 in the pathogenesis and treatment of this highly prevalent genetic dyslipidaemia. FCHL patients, NL relatives and their spouses visited our lipid clinic during the period 2003–2005...

...Ruth C. R. Meex; Esther Phielix; Vera B. Schrauwen-Hinderling; Esther Moonen-Kornips; Gert Schaart; Patrick Schrauwen; Matthijs K. C. Hesselink Exercise training is advocated in insulin resistance and statins are used to treat hyperlipidaemia, two cardiometabolic risk factors often presenting...

...Sandra J. Hamilton; Gerard T. Chew; Timothy M.E. Davis; Gerald F. Watts Dyslipidaemia contributes to endothelial dysfunction and CVD (cardiovascular disease) in Type 2 diabetes mellitus. While statin therapy reduces CVD in these patients, residual risk remains high. Fenofibrate corrects atherogenic...

...Paul K. Hamilton; Sinead M.T. Hughes; Richard D. Plumb; Adrian Devine; William Leahey; Kristopher S. Lyons; Dennis Johnston; Gary E. McVeigh In addition to lowering cholesterol, statins may alter endothelial release of the vasodilator NO and harmful superoxide free radicals. Statins also reduce...

... was to investigate whether LLT (lipid-lowering therapy) with statins could attenuate EPC telomere erosion in patients with CAD (coronary artery disease). The study included 100 patients with stable CAD and 25 subjects without CAD as controls. CAD patients were randomized to 12 months of intensive LLT...

...@dhm.mhn.de ). 11 7 2008 22 8 2008 14 10 2008 14 10 2008 © The Authors Journal compilation © 2009 Biochemical Society 2009 acute coronary syndrome leucocyte mortality myocardial infarction statin unstable angina Considerable evidence exists that elevated...

... s.wort@imperial.ac.uk ). 13 11 2008 27 11 2008 27 11 2008 © The Authors Journal compilation © 2009 Biochemical Society 2009 chronic obstructive pulmonary disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin COPD (chronic...

... disease (COPD) dyspnoea endothelin-1 (ET-1) exercise capacity pulmonary hypertension statin PH (pulmonary hypertension) often complicates the disease course of patients with COPD (chronic obstructive pulmonary disease), and is an indication of a worse prognosis [ 1 ]. An increase in the mean...

...Zhen Huang; Leif Jansson; Åke Sjöholm Patients with diabetes are often treated with a statin for hyperlipidaemia and an ACE (angiotensin-converting enzyme) inhibitor or angiotensin receptor antagonist for hypertension or albuminuria. These drugs may also exert beneficial metabolic effects, causing...

...Jennifer H. Martin; Henry Krum HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors (statins) are well-established therapies in the prevention and treatment of cardiovascular disease, reducing all-cause mortality and cardiovascular events in many disease states. Studies have also suggested...

... in patients with AMI (acute myocardial infarction) and, if so, MMP production may be attenuated by statins (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors) through their cardiovascular protective actions. We studied 30 patients, ten control patients with stable angina pectoris and 20 patients with AMI...

... treatment may be selectively controlling pancreatic islet blood flow, augmenting insulin secretion and thereby improving glucose tolerance. Our findings indicate significant gender-related differences in the vascular response to these agents. Since statins and renin–angiotensin system inhibitors...

... in smokers with normal lipid levels can be improved by a statin treatment. Correspondence: Dr Stefan Agewall (email stefan.agewall@karolinska.se ). 9 2 2006 27 3 2006 12 4 2006 12 4 2006 The Biochemical Society 2006 atherosclerosis cholesterol endothelial function...

...-reactive protein levels and outcomes after statin therapy N. Engl. J. Med. 2005 352 20 28 19 Nissen S. E. Tuzcu E. M. Schoenhagen P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N. Engl. J. Med. 2005 352 29 38 20 Ridker P. M...

...), a CXC chemokine, is present in human coronary atheroma and promotes monocyte–endothelial cell adhesion. In the present study, we examined the effect of pitavastatin (NK-104), a synthetic statin (3-hydroxy-3-methylglutaryl CoA reductase inhibitor), on IL-8 production induced by CRP in human AoEC (aortic...

...Daniele G. BEZERRA; Carlos A. MANDARIM-de-LACERDA The aim of the present study was to investigate the possibility of different effects of the hydrophobic statin simvastatin and the hydrophilic statin pravastatin on the remodelling process in the overloaded left ventricle and renal cortex of SHRs...

...Robert S. ROSENSON; David WOLFF; Christine C. TANGNEY ICAM-1 (intercellular cell-adhesion molecule-1) and VCAM-1 (vascular cell-adhesion molecule-1) are cell-adhesion molecules that have an essential role in monocyte recruitment. In the present study we have investigated (i) whether statins reduce...

... endothelial function fibrinolytic balance inflammation statin Clinical Science (2003) 105, 655 662 (Printed in Great Britain) 655 Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methyl- glutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic...

... in improved endothelial function or in a reduction of markers of inflammation in these patients. adhesion molecule atherosclerosis endothelial function hypercholesterolaemia inflammation statin Correspondence: Dr P L. van Haelst (e-mail P.L.van.Haelst@thorax.azg.nl ). 21 10 2002 14...